Share-based Payment Arrangement, Expense of Kyverna Therapeutics, Inc. from 31 Mar 2023 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kyverna Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2023 to 30 Sep 2025.
  • Kyverna Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,699,000, a 21% decline year-over-year.
  • Kyverna Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,760,000, a 6.5% increase year-over-year.
  • Kyverna Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,357,000, a 276% increase from 2023.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Kyverna Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,760,000 $2,699,000 -$714,000 -21% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $9,474,000 $2,518,000 +$1,234,000 +96% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $8,240,000 $2,161,000 -$117,000 -5.1% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $8,357,000 $1,382,000 +$129,468 +10% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $8,227,532 $3,413,000 +$2,892,000 +555% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $5,335,532 $1,284,000 +$838,000 +188% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $4,497,532 $2,278,000 +$2,277,532 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 $2,220,000 $1,252,532 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $521,000 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $446,000 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $468* 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1

Kyverna Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,357,000 +$6,137,000 +276% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $2,220,000 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.